EUVIMEDEUVIMED entdecken
Crossref

An innovative tailored CAR T cell-redirecting immunotherapy for the treatment of metastatic and refractory Ewing Sarcoma

C Panisello, R Aschero, H Roca-Ho, A Martínez, C Castilla Ramírez, E de Álava, A M Carcaboso, C Bueno, P Menéndez

Klinische Pädiatrie · 01.05.2024 · 236 (03) · 210

DOI: 10.1055/s-0044-1786604 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Klinische Pädiatrie, erschienen am 01.05.2024. Verfasst von C Panisello und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ewing Sarcoma (ES) stands as the second most common bone and soft tissue sarcoma affecting children and young adults. Limited response rates to current multimodal therapies and the lack of actionable targets contribute to dismal long-term survival in patients with metastatic/refractory disease. This highlights the urgent need for developing novel therapeutic approaches. Immunotherapy employing chimeric antigen receptor (CAR)T-cells directed against a tumour-associated antigen (TAA) is a promising therapy with a safe and efficient profile in B-cell malignancies. However, the development of efficient and safe CAR T-cells for the treatment of ES remains challenging due to i) the low abundance of specific and safe TAAs, ii) and the presence of an immunosuppressive tumour microenvironment (iTME) that limits CAR T-cells function. Here, we present an efficient CAR T-cell approach targeting a specific ES-associated antigens with limited expression in healthy tissues. We functionally validated its specificity and safety profiles in robust in vitro and in vivo assays using ES cell lines, primary cells, 3D sarcoma spheroids models which mimic the ES-iTME, and patient-derived animal models. Publication History Article published online: 10 May 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Panisello, C., Aschero, R., Roca-Ho, H., Martínez, A., Ramírez, C. C., Álava, E. D., Carcaboso, A. M., Bueno, C., & Menéndez, P. (2024). An innovative tailored CAR T cell-redirecting immunotherapy for the treatment of metastatic and refractory Ewing Sarcoma. Klinische Pädiatrie, 236(03), 210. https://doi.org/10.1055/s-0044-1786604

Vancouver

Panisello C, Aschero R, Roca-Ho H, Martínez A, Ramírez CC, Álava ED, et al. An innovative tailored CAR T cell-redirecting immunotherapy for the treatment of metastatic and refractory Ewing Sarcoma. Klinische Pädiatrie. 2024;236(03):210. doi:10.1055/s-0044-1786604

BibTeX
@article{Panisello2024,
  author = {Panisello, C and Aschero, R and Roca-Ho, H and Martínez, A and Ramírez, C Castilla and Álava, E de and Carcaboso, A M and Bueno, C and Menéndez, P},
  title = {An innovative tailored CAR T cell-redirecting immunotherapy for the treatment of metastatic and refractory Ewing Sarcoma},
  journal = {Klinische Pädiatrie},
  year = {2024},
  volume = {236},
  number = {03},
  pages = {210},
  doi = {10.1055/s-0044-1786604}
}
Kostenlos starten →